Mon panier

Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Complex Protein (Monomer, MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
HLN-H82E7-25ug
$120.00
HLN-H82E7-200ug
$680.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    HLA-A*0201 & B2M & Survivin (LTLGEFLKL)

  • Source

    Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Complex Protein (HLN-H82E7) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & LTLGEFLKL peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & LTLGEFLKL).

    Predicted N-terminus: Gly 25 & Ile 21

    Request for sequence
  • Molecular Characterization

    Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Complex Protein is produced by co-expression of HLA and B2M loaded with Survivin peptide.

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 40-43 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    HLA-A*0201 & B2M & Survivin (LTLGEFLKL) SDS-PAGE

    Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    HLA-A*0201 & B2M & Survivin (LTLGEFLKL) SEC-MALS

    The purity of Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Complex Protein (Cat. No. HLN-H82E7) is more than 95% and the molecular weight of this protein is around 45-60 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     HLA-A*0201 & B2M & Survivin (LTLGEFLKL) ELISA

    Immobilized Anti-HLA class I Antibody, Human IgG1 (W6/32) at 1 μg/mL (100 μL/well) can bind Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Complex Protein (Cat. No. HLN-H82E7) with a linear range of 0.2-4 ng/mL (QC tested).

    Protocol
  •  HLA-A*0201 & B2M & Survivin (LTLGEFLKL) ELISA

    Immobilized Anti-B2M Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Complex Protein (Cat. No. HLN-H82E7) with a linear range of 0.1-4 ng/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

The HLA-A*02:01&B2M&Survivin (LTLGEFLKL) complex is a key antigen-presenting complex in the immune system. HLA-A*02:01, a major histocompatibility complex (MHC) class I molecule, forms a stable heterodimer with β2-microglobulin (B2M). Subsequently, this dimer binds to the Survivin-derived peptide LTLGEFLKL—a specific epitope of Survivin, an anti-apoptotic protein overexpressed in various tumors. This complex is critical for activating cytotoxic T lymphocytes (CTLs), enabling the immune system to recognize and eliminate tumor cells expressing Survivin.

Progrès de frontière

 
Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte